Recent News

• 08.05.2026 - Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
• 08.04.2026 - Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
• 08.03.2026 - Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
• 07.24.2026 - Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
• 07.22.2026 - Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
• 06.23.2026 - Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
• 06.11.2026 - Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
• 02.04.2026 - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
• 02.02.2026 - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
• 01.26.2026 - Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Recent Filings

• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.08.2026 - 144 Report of proposed sale of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities